Surgical Innovations Group Plc
("Surgical Innovations", the "Company", or the "Group")
Directorate Change
Appointment of Chief Financial Officer
Commercially focused MBA-qualified finance professional brings 20+ years of relevant experience to the Group
Surgical Innovations Group Plc (AIM: SUN), the designer, manufacturer and distributor of innovative technology for minimally invasive surgery, announces the appointment of Chris Martin as Chief Financial Officer ("CFO") and an Executive Director of the Board, effective Monday 10 June 2024. Chris takes over from Interim Financial Consultant, Michael Roper, who will stay on to provide a handover and facilitate a smooth transition.
Chris brings with him over 20 years' experience as a Finance Director in various manufacturing organisations. His most recent role was with Weir Plc, where he served as Regional Finance Director for Europe, North Africa, and Central Asia for six years. Prior to this, from 2004, Chris held Finance Director positions with Jeld-Wen UK, Laing O'Rourke, The Latium Group, and Lafarge S.A.. He obtained an MBA in 2014 and began his finance career in Lafarge Roofing Ltd (part of Lafarge S.A, formerly Redland Plc) in 1990.
CEO, David Marsh, commented: "Chris brings a wealth of experience in growing and improving business performance, managing change, implementing new systems, and developing high-performing teams. We are confident that his expertise and leadership will be valuable to Surgical Innovations as we continue to drive our strategic initiatives forward.
"We would also like to take this opportunity to thank Michael Roper, our Interim Financial Consultant, for his guidance and advice over the past few months."
The following details are disclosed pursuant to Schedule Two Paragraph (g) of the AIM Rules for Companies:
Christopher ("Chris") Jonathan Martin, age 55, holds or has held the following directorships in the past five years:
| Current Directorships |
| None |
| Directorships held within the last five years |
| Weir Mineral Europe Limited |
There are no further disclosures required to be made in relation to AIM Rule 17.
For further information please contact:
| Surgical Innovations Group plc | |||
| David Marsh, CEO Chris Martin, CFO | Tel: 0113 230 7597 | ||
| | | ||
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: 020 7496 3000 | ||
| Aubrey Powell / Oliver Platts | | ||
| | | ||
| Walbrook PR (Financial PR & Investor Relations) | Tel: 020 7933 8780 or si@walbrookpr.com | ||
| Paul McManus / Charlotte Edgar | Mob: 07980 541 893 / 07884 664 686 | ||
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.
Elemental also has exclusive UK distribution for a select portfolio of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.
In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.
We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.
Further information
Further details of the Group's businesses and products are available on the following websites:
To receive regular updates by email, please contact si@walbrookpr.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
